2. Academic Validation
  3. CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis

CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis

  • Nat Commun. 2019 Sep 4;10(1):3981. doi: 10.1038/s41467-019-11662-3.
Yuan Fang 1,  Zhi-Yong Shen 2,  Yi-Zhi Zhan 3 4,  Xiao-Chuang Feng 2,  Ke-Li Chen 5,  Yong-Sheng Li 2,  Hai-Jun Deng 2,  Su-Ming Pan 6,  De-Hua Wu 7,  Yi Ding 8
Affiliations

Affiliations

  • 1 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
  • 2 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
  • 3 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
  • 4 Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
  • 5 Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
  • 6 Department of Radiation Oncology, Yue Bei People's Hospital, Shaoguan, Guangdong Province, 512025, China.
  • 7 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China. [email protected].
  • 8 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China. [email protected].
PMID: 31484922 DOI: 10.1038/s41467-019-11662-3
Abstract

The diverse expression pattern of CD36 reflects its multiple cellular functions. However, the roles of CD36 in colorectal Cancer (CRC) remain unknown. Here, we discover that CD36 expression is progressively decreased from adenomas to carcinomas. CD36 loss predicts poor survival of CRC patients. In CRC cells, CD36 acts as a tumor suppressor and inhibits aerobic glycolysis in vitro and in vivo. Mechanically, CD36-Glypcian 4 (GPC4) interaction could promote the proteasome-dependent ubiquitination of GPC4, followed by inhibition of β-catenin/c-Myc signaling and suppression of downstream glycolytic target genes GLUT1, HK2, PKM2 and LDHA. Moreover, disruption of CD36 in inflammation-induced CRC model as well as APCMin/+ mice model significantly increased colorectal tumorigenesis. Our results reveal a CD36-GPC4-β-catenin-c-myc signaling axis that regulates glycolysis in CRC development and may provide an intervention strategy for CRC prevention.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16928
    99.84%, Mycotoxin